Gallium Ga-68 Gozetotide: uses, dosing, side effects & brands
Gallium Ga-68 Gozetotide is a radioactive diagnostic agent sold in the U.S. under 4 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Radioactive Diagnostic Agent
- Available as
- Injectable · Kit
- Sold as
- 4 products — Locametz, Gallium Ga 68 Gozetotide and Gozellix, and others
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How Locametz is dosed
From the FDA label for Locametz (application NDA215841). Other gallium ga-68 gozetotide products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Use appropriate radiation safety measures and aseptic precautions while handling and administering gallium Ga 68 gozetotide injection. ( 2.1 ) The recommended amount of radioactivity is 111 MBq to 259 MBq (3 mCi to 7 mCi). Administered as slow intravenous injection. ( 2.2 ) Advise patients to be well hydrated prior to the administration and to void immediately prior to and frequently after image acquisition. ( 2.3 ) A diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection. ( 2.6 ) Acquire PET whole body images 50 minutes to 100 minutes after administration. ( 2.7 ) See the full prescribing information for detailed instructions on preparation, administration, imaging, and radiation dosimetry. ( 2 ) 2.1 Radiation Safety – Drug Handling After reconstitution and radiolabeling of LOCAMETZ, the vial contains gallium Ga 68 gozetotide injection. Handle the gallium Ga 68 gozetotide injection with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions (5.2)] . Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling gallium Ga 68 gozetotide injection. Radiopharmaceuticals should be used by or under the control of health care providers who are qualified by specific training and experience in the safe use and handling of radionuclides,…
Everything below is the FDA label for Locametz (injectable). Gallium Ga-68 Gozetotide is also sold as kit, and those are different medicines to take — follow the label for the one you were prescribed.
Locametz side effects
The adverse reactions (incidence ≥ 0.5%) are fatigue, nausea, constipation, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of LOCAMETZ has been established based on three prospective studies of gallium Ga 68 gozetotide in patients with prostate cancer (i.e., Studies 1, 2, and 3). Adverse reactions from these studies are reported below. In Studies 1 and 2 using another formulation of gallium Ga 68 gozetotide injection, 960 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount (mean ± SD) of radioactivity 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi) [see Clinical Studies (14.1, 14.2)] . The most commonly reported adverse reactions were nausea, diarrhea and dizziness, occurring at a rate of < 1%. In a randomized, multicenter, open-label clinical study (NCT03511664, referred to as Study 3) in which gallium Ga 68 gozetotide was used to identify PSMA-positive patients on PET imaging to determine eligibility for PSMA-directed therapy,…
Who shouldn’t take Locametz
None. None. ( 4 )
Locametz drug interactions
Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.
Every gallium ga-68 gozetotide product we track (4)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 3 | Not yet rated | Prescription | Kit | No data | — | View → | |
| 4 | Not yet rated | Prescription | Kit | No data | — | View → |
What people report to the FDA about gallium ga-68 gozetotide
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 166 reports naming gallium ga-68 gozetotide, and the FDA flagged 76% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hot flush28 reports
- erectile dysfunction23 reports
- fatigue13 reports
- pathological fracture9 reports
- rash8 reports
- asthenia7 reports
- cerebral amyloid angiopathy7 reports
- hypothyroidism6 reports
Read these as a signal, not a rate. A report does not mean gallium ga-68 gozetotide caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is Locametz?
Locametz (Gallium Ga-68 Gozetotide) is a radioactive diagnostic agent.
What kind of drug is gallium ga-68 gozetotide?
The FDA classifies gallium ga-68 gozetotide as a radioactive diagnostic agent. A radioactive diagnostic agent is a small dose of a radioactive substance attached to a molecule that travels to a specific organ or tissue. Once there it gives off radiation that a scanner outside the body detects, producing images that show where that tissue is or how it is working. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take gallium ga-68 gozetotide with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run gallium ga-68 gozetotide against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is gallium ga-68 gozetotide sold under?
We track 4 gallium ga-68 gozetotide-containing products in the U.S.: Locametz, Gallium Ga 68 Gozetotide, Gozellix and Illuccix. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does gallium ga-68 gozetotide come in?
Across the brands we track, gallium ga-68 gozetotide is currently marketed as injectable and kit, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic gallium ga-68 gozetotide?
We do not currently list a generic-labelled gallium ga-68 gozetotide product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Gallium Ga-68 Gozetotide: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/gallium-ga-68-gozetotide
- MLA
- “Gallium Ga-68 Gozetotide: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/gallium-ga-68-gozetotide.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for gallium ga-68 gozetotide on DailyMed (NIH) ↗.